Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Sep 20, 2022

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke Market $2.7 Billion by 2029 NEW YORK, Sept. 20, 2022 /PRNewswire/ --...

Sep 6, 2022

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc....

Aug 12, 2022

Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons